Syntheses of Platinum-Sulindac Complexes and Their Nanoparticles as Targeted Anticancer Drugs

Platinum(II)–sulindac complexes [{η2‐C5H4SN(O)}Pt(DMSO){O(C=O)Sulindac}], [{η2‐C5H4SN(O)}PtCl{(S=O)Sulindac}], [{η2‐C5H4SN(O)}PtCl{(S=O)Sulindac–succinimide}], and [{η2‐C5H4SN(O)}PtCl{(S=O)Sulindac–thymidine}] were synthesized that exhibited IC50 values of 2.9–4.8 μm against human oral cancer cells...

Full description

Saved in:
Bibliographic Details
Published in:Chemistry : a European journal 2016-02, Vol.22 (6), p.1926-1930
Main Authors: Hwu, Jih Ru, Tsay, Shwu-Chen, Chuang, Kao Shu, Kapoor, Mohit, Lin, Jia Yu, Yeh, Chen-Sheng, Su, Wu-Chou, Wu, Ping-Ching, Tsai, Tsung-Lin, Wang, Pei-Wen, Shieh, Dar-Bin
Format: Article
Language:English
Subjects:
anticancer drugs
Antitumor agents
biological activity
Cancer
Chemistry
Cytotoxicity
Drugs
Encapsulation
Glycolic acid
Human
Nanoparticles
Oral cancer
Platinum
Polylactide-co-glycolide
Succinimide
Sulindac
Thymidine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Platinum(II)–sulindac complexes [{η2‐C5H4SN(O)}Pt(DMSO){O(C=O)Sulindac}], [{η2‐C5H4SN(O)}PtCl{(S=O)Sulindac}], [{η2‐C5H4SN(O)}PtCl{(S=O)Sulindac–succinimide}], and [{η2‐C5H4SN(O)}PtCl{(S=O)Sulindac–thymidine}] were synthesized that exhibited IC50 values of 2.9–4.8 μm against human oral cancer cells OECM1. The poly(lactic‐co‐glycolic acid) (PLGA) encapsulated [{η2‐C5H4SN(O)}PtCl{(S=O)Sulindac}] also showed cytotoxic activity although less potent than the pristine species. Potency! Two new types of PtII–sulindac complexes were synthesized that exhibited remarkable IC50 values against human cancer cells OECM1 (see scheme). These compounds could be applied for targeted cancer chemotherapeutics.
ISSN:0947-6539
1521-3765
DOI:10.1002/chem.201504915